新世紀醫療(01518.HK)預計年度純利約8000萬至1億元
格隆匯3月10日丨新世紀醫療(01518.HK)發佈公吿,公司預計截至2023年12月31日止年度公司擁有人應占溢利將約人民幣80百萬元至約人民幣100百萬元,而上年度公司擁有人應占虧損約為人民幣297.7百萬元。因此,預期公司將錄得由上年度的公司擁有人應占虧損轉為報吿期內公司擁有人應占溢利。
董事會認為,上述預期財務業績主要由於(i)自2023年第一季度以來集團的業務表現普遍復甦,尤其有關提供兒科服務的業務大幅增長,從而導致集團於報吿期內的收益大幅增加;及(ii)報吿期內若干非流動資產及金融資產減值撥備有所減少,上年度減值撥備合共約人民幣282.3百萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.